

June 2025

Dear Sir / Madam,

Page 1/2

Discontinuation of the Sale and Distribution of Adcortyl (triamcinolone acetonide) in Ireland

Bristol-Myers Squibb (BMS) would like to inform you that the sale and distribution of ADCORTYL (triamcinolone acetonide) will be discontinued in Ireland. This discontinuation affects the Marketing Authorisation listed below.

Product	Strength and Route of administration	License number	Discontinuation effective date
Adcortyl (triamcinolone acetonide)	10 mg/mL Intra-articular/Intradermal Injection	PA 0002/018/003	15 August 2025

BMS' decision to discontinue the supply of this product is not related to any concerns regarding its quality, safety, or efficacy. The availability of Adcortyl will continue until current stock is exhausted, with discontinuation anticipated around 15 August 2025. Please note that this date may vary depending on demand, and the product could potentially run out of stock earlier or later than this timeframe.

While BMS initially projected stock availability until October 2025, an unexpected increase in demand and a temporary manufacturing issue impacting the final batch intended for Ireland have accelerated the depletion timeline. We regret the limited advance notice regarding this matter.

Further information on the discontinuation and recommendations to healthcare professionals is provided hereafter for this medicinal product.**Indications:**

Adcortyl (triamcinolone acetonide) 10 mg/mL is indicated for intra-articular use in the local management of inflammation involving joints, bursae or tendon sheaths such as occurs in rheumatoid arthritis, osteoarthritis, bursitis, synovitis, tendinitis, epicondylitis and trauma; and intradermal use for inflammatory dermal lesions such as lichen simplex, lichen planus, psoriasis, granuloma annulare, keloids and for alopecia.

For further details on the product, please refer to the approved Irish summary of product characteristics (SmPC) and package leaflet, which are available on www.medicines.ie.

Action required by Healthcare Professionals

There is no other branded or generic triamcinolone acetonide available in Ireland. This discontinuation will require health providers to switch patients to other treatments. These alternatives may have a different efficacy and safety profile. For product information on alternatives, you may wish to contact the manufacturers of these products.

Please ensure all relevant personnel are made aware of the content of this letter and that the information is communicated to patients.

Reporting of suspected adverse reactions


Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to HPRA Pharmacovigilance at www.hpra.ie.

Adverse events should also be reported to Bristol-Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com.

Company Contact Point

If you have any medical questions in relation to this communication, please contact Bristol-Myers Squibb Medical Information on 1 800 749 749 or via email at medical.information@bms.com.

Yours sincerely,


Ciara ODwyer (Jun 20, 2025 17:59 GMT+1)

Ciara O'Dwyer - PhD
Associate Director, Medical Lead, Ireland

signed by Bristol-Myers Squibb Pharmaceuticals uc
Plaza 254, Blanchardstown Corporate Park 2,
Dublin 15, D15 T867, Ireland



Job Code: NO-IE-2500021

Date of Preparation: June 2025